Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Placebogecontroleerde challenge-studie met één dosis van gaboxadol bij volwassen mannen met het fragiele X-syndroom (FXS)

8 september 2026 bijgewerkt door: Craig Erickson

This is a single dose, placebo-controlled study. Male subjects aged 18 to 40 years (inclusive) with a diagnosis of FXS. Eligible subjects may enroll in this study comprised of two in home and two in clinic visits each 14 days apart, for a total of four visits. Subjects will be given single dose gaboxadol (10 mg) or matched placebo at each of these visits to take orally. Thus, all enrolled subjects will receive placebo at home and in clinic and receive gaboxadol at home and in clinic in a blinded fashion.

Studie Overzicht

Toestand

Voltooid

Studietype

Ingrijpend

Inschrijving (Werkelijk)

10

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Ohio
      • Cincinnati, Ohio, Verenigde Staten, 45229
        • Cincinnati Children's Hospital Medical Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 40 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Mannelijk

Beschrijving

Inclusion Criteria:

  1. Subject consents to participate, or if they are not their own legal guardian, offers assent supported by legally authorized representative consent
  2. Subject is willing and able to comply with the study procedures as specified in the protocol and to comply with the study drug administration. Caregiver also commits to the study requirements prior to any study-related procedures
  3. Subject and caregiver are both able to understand the spoken national language clearly and caregiver can read and write to complete study assessments
  4. Males age 18 to 40 years (inclusive)
  5. Has FXS with molecular genetic confirmation of the full FMR1 mutation (>200 cysteine-guanine-guanine [CGG] repeats). May have been confirmed historically or at Screening
  6. Is in general good health as deemed by the Investigator, determined by physical examination, medical history, and laboratory tests
  7. If receiving serotonin-selective reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), or serotonin antagonist and reuptake inhibitor (SARI), is on a stable, well-tolerated dose for the previous 3 months with no further changes anticipated
  8. Is not sexually active or can confirm at least one form of contraceptive

Exclusion Criteria:

  1. Any chronic major medical comorbid condition deemed by the Investigator as presenting added risk to the subject, including but not limited to, refractory hypertension, kidney disease, or liver disease
  2. Diagnosed with diabetes (Type 1 or II) or receiving any anti-diabetic medication
  3. Unstable seizure disorder, defined by any seizure within 6 months prior to baseline visit and/or a change in any anti-convulsant drug dosing in the 60 days prior to study consent
  4. Changes in psychotropic or anti-convulsant (where taken for reasons other than seizure control) drug treatment within 30 days prior to Screening
  5. Significant changes in any educational, behavioral, and/or dietary interventions the month prior to Screening
  6. Planned initiation of new, or modification of ongoing, interventions during the study
  7. Unable or unwilling to take oral medication (whole capsule, despite assistance with a spoonful of applesauce, yoghurt, or equivalent liquid food)
  8. Consumption of liver enzyme inducers or inhibitors including and not limited to foods, medicines, herbal remedies and supplements three days prior to any Visit. Foods or beverages containing CYP3A4/5 inhibitors (e.g., grapefruit, pomegranate, pomelo, and star fruit) should be avoided before taking study medication and for up to 1 hour post dose throughout the study
  9. Has abnormal baseline laboratory assessments including, but not limited to, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) or total bilirubin >1.5 × the upper limit of normal (ULN), serum creatinine >1.5 x ULN or other clinically relevant laboratory abnormality
  10. Has a clinically significant heart rate or blood pressure (BP) at Screening as judged by the Investigator
  11. Has received an investigational drug in any prior clinical study within 30 days or 5 half-lives (whichever is longer) prior to Screening

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Fundamentele wetenschap
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Verviervoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Placebo in lab, Gaboxadol in home, Gaboxadol in lab, Placebo in home

Individuals in this condition received Placebo in lab, Gaboxadol in home, Gaboxadol in lab, then Placebo in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

Experimenteel: Gaboxadol in lab, Gaboxadol in home, Placebo in lab, Placebo in home

Individuals in this condition received Gaboxadol in lab, Gaboxadol in home, Placebo in lab, then Placebo in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

Experimenteel: Placebo in lab, Placebo in home, Gaboxadol in lab, Gaboxadol in home

Individuals in this condition received Placebo in lab, Placebo in home, Gaboxadol in lab, then Gaboxadol in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

Experimenteel: Gaboxadol in lab, Placebo in home, Placebo in lab, Gaboxadol in home

Individuals in this condition received Gaboxadol in lab, Placebo in home, Placebo in lab, then Gaboxadol in home.

Drug: Gaboxadol 10 mg as a single dose (two 5mg capsules)

Two placebo capsules

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Target Engagement of Gaboxadol Treatment on EEG Power
Tijdsspanne: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Changes in EEG recordings with gaboxadol treatment (assessed at pre-dose, 60 minutes post-dose, average response across home and lab reported). compared with pre-dose on resting theta, alpha and gamma band absolute power. Absolute power measures reflect the median power averaged across 129 electrodes in μV²/Hz. Means are presented using the average of home and lab values.

Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
Target Engagement of Gaboxadol Treatment on Auditory Chirp
Tijdsspanne: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Changes in EEG recordings with gaboxadol treatment (60-90 minutes post-dose compared with pre-dose on brain response to auditory chirp stimuli), as measured by intertrial phase coherence (ITC). Means are presented using the average of home and lab values.

Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
To Investigate the Feasibility of Home Research Visits and Procedures in Adult Males With FXS
Tijdsspanne: Pre-dose, 60 minutes post-dose

Quality and test-retest reliability of assessments performed at home compared with the hospital setting. This includes blood testing for Fragile X messenger ribonucleoprotein (FMRP: range of 0-40 picomolar) and eye-tracking of eye gaze to eye regions when viewing faces (range of value from 0 percent to 100 percent; higher values are associated with a neurotypical phenotype).

Pre-dose, 60 minutes post-dose
To Investigate the Feasibility of High Density EEG Recording at Home in Adult Males With FXS
Tijdsspanne: Pre-dose, across four sessions (2 in-lab, 2 in-home), up to day 42

This endpoint examined the reliability of pre-dose resting-state EEG absolute power estimates between in-lab and in-home assessments using intraclass correlation (ICC). ICCs were calculated separately for 129 electrodes using absolute power estimates (μV²/Hz). The reported ICC represents the mean ICC across electrodes, with the standard deviation reflecting variability in ICC values across electrodes. whole-head, pre-dose resting state EEG power estimates from data collected in-lab vs in-home using intraclass correlation (ICC).

Pre-dose, across four sessions (2 in-lab, 2 in-home), up to day 42
To Potentially Explore the Pharmacokinetics of Gaboxadol Treatment in Single-dose Trial Design
Tijdsspanne: Sixty minutes post-dose on 4 study visits, up to day 42

PK profile (the level of gaboxadol in human plasma) will be obtained at 60 +/- 10 minutes post-dose only).

Sixty minutes post-dose on 4 study visits, up to day 42
To Investigate the Effect of Gaboxadol Treatment on Neuropsychological Assessments
Tijdsspanne: Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42

Changes in cognitive and neuropsychological assessment measures with gaboxadol treatment (RBANS List Learning). During the RBANS List Learning subtests, participants listen to a list of 10 words and repeat back as many as they can remember four times, for a maximum score of 40. Change scores were calculated by subtracting pre-dose words remembered from post-dose words remembered, with positive scores meaning an improvement in memory.

Pre-dose compared to 60 minutes post-dose on 4 study visits, up to day 42
To Investigate the Effect of Gaboxadol Treatment on Eye Tracking Assessments
Tijdsspanne: Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

Change in eye tracking outcomes (60-90 minutes post-dose compared to pre-dose on percent viewing of social versus geometric scene

Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42
To Investigate the Effect of Gaboxadol Treatment on Clinician-rated Measures
Tijdsspanne: Post-dose on 4 study visits, up to day 42

Score on the Clinical Global Impressions - Improvement (CGI-I) scale, a clinician rating scale with "1" anchored to "very much improved" and "7" anchored to "very much worse."

Post-dose on 4 study visits, up to day 42
To Determine Whether FMRP Levels Predict Treatment Response
Tijdsspanne: Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

Relationship between FMRP (Fragile X messenger ribonucleoprotein) level and degree of change (baseline/screen to post-dose) across measures

Baseline compared to 60 minutes post-dose on 4 study visits, up to day 42

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Medewerkers

Onderzoekers

  • Hoofdonderzoeker: Cragi A Erickson, MD, Children's Hospital Medical Center, Cincinnati

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

29 januari 2024

Primaire voltooiing (Werkelijk)

13 mei 2025

Studie voltooiing (Werkelijk)

24 juni 2025

Studieregistratiedata

Eerst ingediend

8 maart 2024

Eerst ingediend dat voldeed aan de QC-criteria

19 maart 2024

Eerst geplaatst (Werkelijk)

28 maart 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

30 september 2026

Laatste update ingediend die voldeed aan QC-criteria

8 september 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren